)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
BioInvent International
BioInvent International (BINV) investor relations material
BioInvent International Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary2 Mar, 2026
Pipeline and clinical programs
Two lead antibodies, BI-1808 (anti-TNFR2) and BI-1206 (anti-FcyRIIB), have demonstrated clinical proof of concept in ovarian cancer, NSCLC, CTCL, uveal melanoma, and NHL.
BI-1808 shows single-agent activity and durable responses in ovarian cancer and CTCL, with potential to become a new standard of care.
BI-1206 targets resistance mechanisms in follicular lymphoma and solid tumors, showing significant efficacy in combination regimens.
Multiple Phase 2a readouts are expected in mid-2026 for both programs, with pivotal studies planned for 2027.
Complete and partial responses have been observed across all clinical programs.
BI-1808 (anti-TNFR2) highlights
Demonstrates a differentiated mechanism by depleting regulatory T cells, activating myeloid cells, and expanding CD8+ T cells.
In ovarian cancer, BI-1808 plus pembrolizumab achieved a 24% ORR and 57% DCR, with durable responses and manageable safety profile.
In CTCL, monotherapy showed a 46% ORR and 92% DCR, with early immune activation and favorable safety.
Potential blockbuster opportunity in ovarian cancer and CTCL, addressing large, underserved markets.
Planned data releases in 2026 include Phase 2a updates for both monotherapy and combination regimens.
BI-1206 (anti-FcyRIIB) highlights
Blocks a key resistance pathway to antibody therapies, resensitizing tumors to CD20 therapy in follicular lymphoma.
In combination with rituximab, BI-1206 achieved a 59% ORR and 41% CRR in follicular lymphoma, with long-lasting responses.
Triplet therapy (BI-1206 + rituximab + acalabrutinib) showed an 80% ORR and 100% DCR in NHL, with good tolerability.
In solid tumors, BI-1206 plus pembrolizumab demonstrated durable responses in anti-PD-1 refractory melanoma and uveal melanoma.
Ongoing Phase 2a studies in NSCLC and uveal melanoma, with first data expected in H2 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next BioInvent International earnings date
Q1 202629 Apr, 2026
BioInvent International
Next BioInvent International earnings date
Q1 202629 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage